130 citations
,
February 2018 in “Journal of Investigative Dermatology” This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.
22 citations
,
May 2017 in “Journal of dermatological treatment” This study found that BD 1/4 dilution was the most effective corticosteroid concentration for intralesional injection to treat localized alopecia areata in adults, with fewer adverse effects than TA.
8 citations
,
October 2016 in “Experimental dermatology” This paper proposes that the induction of HF-specific neo-antigens by peripheral CD8+ T cells may maintain self-tolerance but could also lead to immunopathology in conditions like alopecia areata.
196 citations
,
September 2016 in “JCI insight” This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.
15 citations
,
April 2016 in “The Journal of Dermatology” This study found that patients with alopecia areata and less than 50% hair loss showed a good response to pulse therapy with methylprednisolone, while those with more extensive hair loss also improved but required more courses.
65 citations
,
December 2015 in “Experimental dermatology” This study found that both Th1 and Th2 immune responses, along with IL-23 and IL-32 cytokine pathways, are active in alopecia areata lesions, and corticosteroid injections significantly altered these immune markers.
21 citations
,
November 2015 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This review discusses recent therapeutic approaches for alopecia areata, including the use of Janus kinase inhibitors and interleukin-2, and reports no new clinical results.
176 citations
,
August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” This study identified a distinct cytokine activation signature in alopecia areata, involving TH2, TH1, IL-23, and IL-9/TH9 pathways, suggesting potential targeting strategies similar to those in psoriasis and atopic dermatitis.
62 citations
,
June 2015 in “The Journal of Dermatology” This study found that patients with alopecia areata had higher levels of Th17 cells and lower levels of regulatory T cells compared to healthy controls, suggesting an immune imbalance in these patients.
184 citations
,
February 2015 in “EBioMedicine” This study observed that baricitinib treatment led to significant improvement in a patient's alopecia areata symptoms and suggests further clinical trials to explore its potential as a treatment.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
421 citations
,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
717 citations
,
June 2010 in “Nature” This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.
